Not yet recruiting
Acute lymphocytic leukaemia+1
Not yet recruitingRegistered drugNo placebo
A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.
Registered drugNo placebo
- Disease:Acute lymphocytic leukaemiaAcute lymphocytic leukaemia recurrent
- Substances:BlinatumomabCyclophosphamide+5
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Blinatumomab
